Ketoconazole: Difference between revisions
Elcatracho (talk | contribs) |
|||
| (10 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antifungal | *Type: [[Antifungal]] | ||
*Dosage Forms: | *Dosage Forms: Tablet, 200mg | ||
*Routes of Administration: PO, topical | *Routes of Administration: PO, topical | ||
*Common Trade Names: | *Common Trade Names: Nizoral | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Fungal infections=== | |||
*200-400mg PO qday | |||
* | ===Prostate cancer=== | ||
*400mg PO q8h | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Fungal infectionss (2 years and up)=== | |||
*3.3-6.6mg/kg PO qday | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C, adverse events have been seen in animal studies | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Excreted in breast milk, not recommended by manufacturer. | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: no adjustment | *Adult: no adjustment | ||
| Line 31: | Line 33: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hepatotoxicity | *[[Hepatotoxicity]] | ||
*Adrenal insufficiency | *[[Adrenal insufficiency]] | ||
*Hypersensitivity reaction | *[[Hypersensitivity reaction]] | ||
*Anaphylaxis | *[[Anaphylaxis]] | ||
*Thrombocytopenia | *[[Thrombocytopenia]] | ||
*Leukopenia | *[[Leukopenia]] | ||
*Hemolytic | *[[Hemolytic anemia]] | ||
===Common=== | ===Common=== | ||
*Nausea | *[[Nausea]] | ||
*Abdominal | *[[Abdominal pain]] | ||
*Dizziness | *[[Dizziness]] | ||
*Diarrhea | *[[Diarrhea]] | ||
*Headache | *[[Headache]] | ||
*Pruritis | *[[Pruritis]] | ||
*Lethargy | *[[Lethargy]] | ||
*Gynecomastia | *[[Gynecomastia]] | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 60: | Line 62: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | |||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 03:19, 8 March 2021
Administration
- Type: Antifungal
- Dosage Forms: Tablet, 200mg
- Routes of Administration: PO, topical
- Common Trade Names: Nizoral
Adult Dosing
Fungal infections
- 200-400mg PO qday
Prostate cancer
- 400mg PO q8h
Pediatric Dosing
Fungal infectionss (2 years and up)
- 3.3-6.6mg/kg PO qday
Special Populations
- Pregnancy Rating: C, adverse events have been seen in animal studies
- Lactation risk: Excreted in breast milk, not recommended by manufacturer.
Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
Hepatic Dosing
- Adult: contraindicated in liver disease
- Pediatric: contraindicated in liver disease
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hepatotoxicity
- Adrenal insufficiency
- Hypersensitivity reaction
- Anaphylaxis
- Thrombocytopenia
- Leukopenia
- Hemolytic anemia
Common
Pharmacology
- Half-life: 8 h
- Metabolism: Liver (CYP450)
- Excretion: feces > urine
Mechanism of Action
- Inhibits synthesis of cell membrane ergosterol